To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma

Sponsor
Beijing GoBroad Hospital
Study ID
NCT07179484
Status
Recruiting
Apply to this trial

Conditions

  • Gastroesophageal Junction Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • CT041 autologous CAR T-cell injection — DRUG
    The planned dose of CT041 is 2.5×108 cells. The participants are recommended to receive only a single infusion or multiple infusions (up to 3 infusions) according to the safety and efficacy data of the participants per the investigator. The dose and method of re-infusion are the same as the first infusion. Lymphodepletion pretreatment should be given before re-infusion, and the requirements before lymphodepletion pretreatment and cell infusion should also be met before re-lymphodepletion pretreatment or re-infusion.

Study Details

To evaluate the efficacy of CT041 in sequential treatment after first-line treatment of advanced gastric/esophagogastric junction adenocarcinoma

Key Dates

First listed
Sep 17, 2025
Start date
Oct 22, 2025
Status verified
Sep 2025
Primary completion
Sep 1, 2027
Completion
Sep 1, 2028

Study Design

Enrollment
20 participants (estimated)

Primary Outcome Measure

To evaluate the efficacy of CT041 in sequential treatment after first-line treatment of advanced gastric/esophagogastric junction adenocarcinoma [ Time Frame: For 18 months ]

Central Contacts

Related Studies